ARTICLE | Company News
Isis Pharmaceuticals, KineMed, CHDI Foundation Inc. deal
February 25, 2013 8:00 AM UTC
Isis will use biomarkers from KineMed and the not-for-profit foundation to develop an antisense therapeutic for Huntington's disease (HD). KineMed and the foundation are partnered to use KineMed's iso...